Source link : https://www.newshealth.biz/health-news/neutral-result-with-novel-agent-in-diabetic-cardiomyopathy/
ATLANTA, GA — A multicenter controlled trial testing the ability of an aldose reductase inhibitor to stabilize early-stage asymptomatic diabetic cardiomyopathy missed its primary endpoint, researchers reported. But several signals of benefit support a hypothesis that heart failure might be preventable if the polyol pathway, which features upregulation of aldose reductase, is inhibited at an […]
Author : News Health
Publish date : 2024-04-16 10:42:45
Copyright for syndicated content belongs to the linked Source.